The DOI matches its Crossref record, with a small difference in title or year; 32 of the 32 references it cites were found in a registry or an index.
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Open accessAbstract
BACKGROUND: Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin. METHODS: In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulation. Study drugs were administered for up to 12 months. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was major bleeding. RESULTS: A total of 3365 patients were included in the intention-to-treat analyses (median treatment duration, 351 days). The primary efficacy outcome occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor bleeding were 2.7%, 2.0%, and 1.8%, respectively. The incidence of adverse events was similar in all three groups. CONCLUSIONS: Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates. (Funded by Bayer Pharmaceuticals; EINSTEIN CHOICE ClinicalTrials.gov number, NCT02064439 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Consequently, several studies have investigated the role of aspirin for the secondary prevention of VTE. 309,314,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“and a single study comparing 2 doses of the direct oral anticoagulant rivaroxaban and aspirin found that anticoagulation was more effective than aspirin without an increase in bleeding rates. 314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Self-citationThe Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
Research works printed but not linked: 1
- 2012, MMWR Morb Mortal Wkly Rep, 61, 401
Cited by
Items 301–400 of 786
Bradbury, C. A., Buckley, T., Sun, Y. Z., Rose, P. E., & Fitzmaurice, D. A. (2019) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.11.011 · Cited by 9
Bortoluzzi, C., Bernardi, E., Camporese, G., Noventa, F., Ceccato, D., Tonello, C., Hong, N. V., Campello, E., Simion, C., Imbalzano, E., et al. (2022) · Life · doi:10.3390/life12101657 · Cited by 9
Transgender Medicine and Risk of Venous Thromboembolism
van Bunderen, C. C., Leentjens, J., & Middeldorp, S. (2022) · Hämostaseologie · doi:10.1055/a-1891-8158 · Cited by 9
Chatani, R., Yamashita, Y., Morimoto, T., Muraoka, N., Umetsu, M., Nishimoto, Y., Takada, T., Ogihara, Y., Nishikawa, T., Ikeda, N., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae028 · Cited by 9
Kommission für Klinische Kardiovaskuläre Medizin der, D. G. K., Konstantinides, S., Lankeit, M., Erbel, C., & Tiefenbacher, C. (2020) · Der Kardiologe · doi:10.1007/s12181-020-00389-x · Cited by 9
Bikdeli, B., Khairani, C. D., Barns, B. M., Rosovsky, R. P. G., Jiménez, D., Monréal, M., Sylvester, K. W., Middeldorp, S., Bates, S. M., Krumholz, H. M., et al. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106714 · Cited by 9
Clinical Studies with Anticoagulants that Have Changed Clinical Practice
Hirsh, J., de Vries, T. A. C., Eikelboom, J. W., Bhagirath, V. C., & Chan, N. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1760330 · Cited by 10
Wells, P. S., Prins, M. H., Beyer‐Westendorf, J., Lensing, A. W. A., Haskell, L. P., Levitan, B. S., Laliberté, F., Ashton, V., Xiao, Y., Lejeune, D., et al. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.08.1059 · Cited by 9
Self-citationUtility of the DASH score after unprovoked venous thromboembolism; a single centre study
MacDonald, S. G., Chengal, R., Hanxhiu, A., Symington, E. M., Sheares, K. K. K., Besser, M. W., & Thomas, W. (2018) · British Journal of Haematology · doi:10.1111/bjh.15597 · Cited by 9
Rivaroxaban for Prevention and Treatment of Venous Thromboembolism
Chan, N., & Weitz, J. I. (2019) · Future Cardiology · doi:10.2217/fca-2018-0076 · Cited by 9
Self-citationPrevention of Postpartum Venous Thromboembolism
Clinton, C. M., Kuller, J. A., & James, A. (2019) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000714 · Cited by 9
The paradoxical association between pulmonary embolism and COPD
Bertoletti, L. (2017) · European Respiratory Journal · doi:10.1183/13993003.00959-2017 · Cited by 9
Howe, Z., Naville-Cook, C., & Cole, D. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1770-7 · Cited by 8
Dix, C. H. K., Doyle, A. J., Breen, K. A., & Hunt, B. J. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2379-7288 · Cited by 8
Male, C., Lensing, A. W. A., Chan, A. K. C., Kenet, G., Young, G. A., Bhat, R. V., Pap, A. F., Kubitza, D., Prins, M. H., Monagle, P., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00067-5 · Cited by 8
Self-citationThe fibrinolytic system in disease: From molecular pathways to clinical outcomes
Alibrahim, M. N., Sahli, K. A., & Alshehri, F. S. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109504 · Cited by 10
Rivaroxaban in the treatment of TEK ‐related venous malformation
Oo, H. P., Pasricha, S., Thompson, B. A., Winship, I., & Scardamaglia, L. (2022) · Australasian Journal of Dermatology · doi:10.1111/ajd.13856 · Cited by 8
Fan, G., Wang, D., Zhang, M., Luo, X., Zhai, Z., & Wu, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.979911 · Cited by 9
Ma, S., Fan, G., Xu, F., Zhang, X., Chen, Y., Tao, Y., Li, Y., Lyu, Y., Yang, P. B., Wang, D., et al. (2024) · Thrombosis Journal · doi:10.1186/s12959-023-00576-2 · Cited by 9
Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use
Khairani, C. D., Bejjani, A., Assi, A. A., Porio, N. D., Talasaz, A. H., Piazza, G., Cushman, M., & Bikdeli, B. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102424 · Cited by 9
Direct oral anticoagulants and travel-related venous thromboembolism
Chamnanchanunt, S., & Rojnuckarin, P. (2018) · Open Medicine · doi:10.1515/med-2018-0085 · Cited by 8
Oral Rivaroxaban in Symptomatic Deep Vein Thrombosis
Farhan, A. F., Bukhari, M., Umar, J., & Raza, M. (2019) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2019.09.814 · Cited by 8
The year 2017 in cardiology: aorta and peripheral circulation
Aboyans, V., Brækkan, S. K., Mazzolai, L., Sillesen, H. H., Venermo, M. A., Carlo, M. D., & the ESC Working Group on Aorta and Peripheral Vascular Diseases (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx800 · Cited by 9
Kaneda, K., Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.11.022 · Cited by 8
How, J., Story, C. M., & Connors, J. M. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1880844 · Cited by 8
Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes
Brunton, N. E., Wysokiński, W. E., Hodge, D. O., Vlazny, D. T., Houghton, D. E., & Casanegra, A. I. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12500 · Cited by 8
When and how to use direct oral anticoagulants in patients with advanced chronic liver disease?
Maria, C. D., Galante, A., Fasoli, A., & Gottardi, A. D. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.07.006 · Cited by 8
Prophylactic anticoagulants for non-hospitalised people with COVID-19
Santos, B. C., Flumignan, R. L., Civile, V. T., Atallah, Á. N., & Nakano, L. C. U. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015102 · Cited by 8
Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants
Rosovsky, R. P. G., & Merli, G. J. (2017) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2017.07.003 · Cited by 8
Jiang, S., Du, L., & Ni, C. (2017) · International Journal of Pharmacology · doi:10.3923/ijp.2018.1.8 · Cited by 9
Kalinin, R. E., Suchkov, I. A., & Николаевич, Ш. И. (2019) · Nauka molodykh (Eruditio Juvenium) · doi:10.23888/hmj201971113-121 · Cited by 8
Djulbegovic, M., Lee, A. I., & Chen, K. M. (2019) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13194 · Cited by 9
Κάρτας, Α., Doundoulakis, I., Ntiloudi, D., Koutsakis, A., Kosmidis, D., Rampidis, G. P., Apostolopoulou, S. C., Frogoudaki, A., Tzifa, A., Avramidis, D., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038012 · Cited by 9
Kanthi, Y. M., & Piazza, G. (2018) · Vascular Medicine · doi:10.1177/1358863x18770529 · Cited by 8
Wang, M. K., Baskaran, G., Razeghi, G., Ma, R., Park, L., Tannu, M., Devereaux, P. J., McIntyre, W. F., Healey, J. S., Shoamanesh, A., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02132 · Cited by 8
Are the correct outcomes being measured in studies of oral anticoagulants? A systematic survey
Wang, M., Chen, Z., Wong, M., Thabane, L., Mbuagbaw, L. C. E., Siegal, D. M., Gal, G. L., & Holbrook, A. M. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.02.016 · Cited by 8
Volkl, A. A., Moore, K. T., Haskell, L. P., & Barnathan, E. S. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00579-4 · Cited by 7
Self-citationDirect Oral Anticoagulants for Pulmonary Embolism
Pizzi, R., Cimini, L. A., Ageno, W., & Becattini, C. (2024) · Hämostaseologie · doi:10.1055/a-2105-8736 · Cited by 9
Costanzo, L., Paola, F. D., Pedi, A., Failla, G., & Mangiafico, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082394 · Cited by 8
Anticoagulants: From chance discovery to structure-based design
Chan, N., Carlin, S., & Hirsh, J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100037 · Cited by 7
Ageno, W., & Hunt, B. J. (2018) · European Heart Journal Supplements · doi:10.1093/eurheartj/suy015 · Cited by 7
Coleman, C. I., Turpie, A. G. G., Bunz, T. J., Beyer‐Westendorf, J., & Baker, W. L. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.11.040 · Cited by 7
Self-citationMethodological Issues and Controversies in COVID-19 Coagulopathy: A Tale of Two Storms
Berkman, S. A., & Tapson, V. F. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620945398 · Cited by 7
Cancer and Thrombosis: New Treatments, New Challenges
Dahm, A. E. A. (2021) · Medical Sciences · doi:10.3390/medsci9020041 · Cited by 7
Direct oral anticoagulant dose selection: Challenging cases
Carlin, S., & Eikelboom, J. W. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15536 · Cited by 7
Wang, B., Jiang, C., Zhang, Y., Li, X., & Xu, H. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02849-6 · Cited by 7
Liu, Z., Tan, J., Deng, Y.-R., Hua, L., & Guo, T. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120414 · Cited by 7
Lu, K., Liao, Q.-Q., Zhu, K., Yao, Y., Cui, X.-J., Chen, P., Bi, Y., Zhong, M., Zhang, H., Tang, J.-C., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02717-5 · Cited by 9
van der Pol, L. M., Mairuhu, A. T. A., Leroyer, C., Couturaud, F., Huisman, M., Klok, F. A., & Tromeur, C. (2018) · Seminars in Interventional Radiology · doi:10.1055/s-0038-1642622 · Cited by 10
Extended anticoagulation for unprovoked venous thromboembolism
Castellucci, L. A., de Wit, K., Garcia, D. A., Ortel, T. L., & Gal, G. L. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12121 · Cited by 7
Riva, L., Ageno, W., Pasquale, G. D., Agnelli, G., & Rubboli, A. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.07.133 · Cited by 7
Real-world assessment of off-label direct oral anticoagulant dosing for venous thromboembolism
Saunders, J. A., Gustafson, W. L., Vazquez, S. R., Jones, A. E., & Witt, D. M. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01904-y · Cited by 7
Gressenberger, P., Rief, P., Jud, P., Gütl, K., Muster, V., Ghanim, L., Brodmann, M., & Gary, T. (2019) · Europe PMC (PubMed Central) · Cited by 7
Wang, J., Lim, H. Y., Brook, R., Lai, J., Nandurkar, H. H., & Ho, P. W. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-022-02686-6 · Cited by 8
Berger, J. S., Seheult, R., Laliberté, F., Crivera, C., Lejeune, D., Xiao, Y., Schein, J. R., Lefèbvre, P., & Kaatz, S. S. (2017) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12050 · Cited by 7
Using non-vitamin K oral anticoagulants in specific patient populations: a study of Korean cases
-, I. C. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s204377 · Cited by 7
Hybrid Strategy to Prevent Venous Thromboembolism after Joint Arthroplasty
Garcia, D. A. (2018) · New England Journal of Medicine · doi:10.1056/nejme1716534 · Cited by 7
Piazza, G. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac731 · Cited by 8
Pathway for the Diagnosis and Management of Pulmonary Embolism
Herzog, E., Elbaz‐Greener, G., Planer, D., Koren, T., Amir, O., Shapiro, J. M., & Kalish, Y. (2021) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000252 · Cited by 6
Direct Oral Anticoagulants for Inferior Vena Cava Agenesis
Iarossi, M., & Hermans, C. R. J. R. (2023) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296231200224 · Cited by 6
Kempers, E. K., van der Zande, J. A., Janssen, P. M., Cornette, J. M. J., Roos‐Hesselink, J. W., & Kruip, M. J. H. A. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102295 · Cited by 6
Guidelines on deep vein thrombosis of the Brazilian Society of Angiology and Vascular Surgery
Sobreira, M. L., Marques, M. A., Paschôa, A. F., Ribeiro, A. J. A., Casella, I. B., Burihan, M. C., Matielo, M. F., Soares, R. D. A., de Araújo, W. J. B., Joviliano, E. É., et al. (2024) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202301072 · Cited by 8
Alam, U., Ali, M. A., Ansab, M., Rath, S., Khattak, F., Bacha, Z., Siddiqui, H. T., Sajjad, F., Afridi, A., Afridi, Z., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04388-1 · Cited by 6
Lungenarterienembolie: Status 2018
Wilkens, H., & Held, M. (2018) · Deutsches Ärzteblatt · doi:10.3238/perspneumo.2018.06.15.002 · Cited by 7
Folkerts, K., Broughton, J., Sheikh, U., & Mckaig, S. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1658589 · Cited by 8
Wang, J., TACEY, M. A., & Ho, P. W. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02101-y · Cited by 7
Direct Oral Anticoagulants in Antithrombin Deficiency: Initial Experience in a Single Center
Bhoelan, S., Mulder, R., Lukens, M. V., & Meijer, K. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1715647 · Cited by 6
Fukamachi, D., Okumura, Y., Fukuda, I., Nakamura, M., Yamada, N., Takayama, M., Maeda, H., Yamashita, T., Ikeda, T., Mo, M., et al. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2070379 · Cited by 6
Chaudhury, P., Alvarez, P. A., Michael, M., Saad, M. S., Bishop, G. J., Hanna, M. A., Menon, V., Starling, R. C., Spyropoulos, A. C., Desai, M. Y., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025342 · Cited by 6
An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism
Martins, M. D. A., Silva, T. F., & Fernandes, C. J. C. D. S. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01384-7 · Cited by 7
Rivaroxaban for Left Ventricular Thrombus
Yassin, A., Abubakar, H., Mishra, T., Adam, O. A., Hartman, M., Pahuja, M., & Shokr, M. (2018) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000726 · Cited by 6
Freed, J. A., & Bauer, K. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00014-5 · Cited by 6
Banham-Hall, E., Allison, A., Santarsieri, A., Gohel, M., Crowley, M. P., Sheares, K. K. K., & Thomas, W. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02193-6 · Cited by 6
Vasanthamohan, L., Boonyawat, K., Chai‐Adisaksopha, C., & Crowther, M. A. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15427 · Cited by 6
Lin, Y., Lin, M., Wu, V. C., Chen, Y., Chang, J.-J., Chu, P., Lip, G. Y. H., & Chen, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.775564 · Cited by 6
Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism
Kimpton, M., & Carrier, M. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1601699 · Cited by 6
Kalinin, R. E., Suchkov, I. A., MZHAVANADZE, N. D., & Povarov, V. O. (2019) · Journal of Venous Disorders · doi:10.17116/flebo20191301121 · Cited by 6
Palareti, G., Legnani, C., Antonucci, E., Zorzi, S., Bignamini, A. A., Lodigiani, C., Tosetto, A., Bertù, L., Pengo, V., Testa, S., et al. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02381-5 · Cited by 6
Self-citationBeer, J. H., & Bonetti, N. R. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx702 · Cited by 7
Verlängerte Sekundärprophylaxe nach venöser Thromboembolie
Bauersachs, R. M. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-113679 · Cited by 5
Self-citationScheres, L. J. J., & Middeldorp, S. (2024) · Hematology · doi:10.1182/hematology.2024000593 · Cited by 5
Direct oral anticoagulant failure in patients with venous thromboembolism—why and what next?
Swan, D., Turner, R., Grove, E. L., Schulman, S., & Thachil, J. V. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.03.026 · Cited by 6
Vlazny, D. T., McBane, R. D., Casanegra, A. I., Hodge, D. O., Lang, T. R., Wysokiński, W. E., Peterson, L. G., & Houghton, D. E. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102878 · Cited by 5
Poli, D., Parisi, R., Antonucci, E., Barcella, L., Bucherini, E., Chistolini, A., Giorgio, A. D., Giulio, R. D., Nisio, M. D., Elmi, G., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.07.034 · Cited by 5
Akhtar, M., Nabi, R., Saadia, S., Ashraf, D. A., Hassan, S. M., Akhtar, M., Zia, M. A., & Ahmed, R. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07759-1 · Cited by 5
Ibrahim, A. M., Shalabi, L., Zreigh, S., Tawfik, A. M., Hamed, B. M., Elsawy, M., Pathak, A., Mamas, M. A., Andò, G., Elgendy, I. Y., et al. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109476 · Cited by 5
Li, D., Liu, Y., Song, Y. H., & Wen, A. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2026002 · Cited by 5
Spence, J. D. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01202-w · Cited by 5
Hosokawa, K., Abe, K., Kishimoto, J., Kobayakawa, Y., Todaka, K., Tamura, Y., Tatsumi, K., Inami, T., Ikeda, N., Taniguchi, Y., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061225 · Cited by 5
Chistolini, A., Serrao, A., Assanto, G. M., Genoese, A., Baldacci, E., Ligia, S., Breccia, M., & Santoro, C. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05369-1 · Cited by 5
Cancer-Associated Thrombosis: Management of a Patient With an Isolated Calf Deep Vein Thrombosis
Soff, G. A. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01905 · Cited by 5
Laganà, A., Assanto, G. M., Masucci, C., Passucci, M., Donzelli, L., Serrao, A., Baldacci, E., Santoro, C., & Chistolini, A. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.020 · Cited by 6
Anticoagulation Management Post Pulmonary Embolism
Naoum, J. J. (2024) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1338 · Cited by 9
Seoane, L., Cortes, M. M., Cancela, M. E. A., Furmento, J., Baranchuk, A. M., & Conde, D. G. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1484281 · Cited by 5
Quelle est la durée du traitement anticoagulant pour une EP/TVP proximale ?
Couturaud, F., Girard, P., Laporte, S., & Sanchez, O. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.05.022 · Cited by 5
Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
Hendriks, S. V., Klok, F. A., Stenger, W. J. E., Mairuhu, A. T. A., Eikenboom, J. C. J., Fogteloo, J., & Huisman, M. V. (2020) · TH Open · doi:10.1055/s-0040-1713683 · Cited by 5
Hoffmann, C., Leven, C., Mao, R. L., MOREUIL, C. D., & Lacut, K. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.05.026 · Cited by 6
Parascandolo, E., & Eisen, A. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1806712 · Cited by 6
Wang, J., Lim, H. Y., & Ho, P. W. (2021) · Hemato · doi:10.3390/hemato2010003 · Cited by 5
MacLehose, R. F., Zakai, N. A., Walker, R. F., Alonso, Á., Adams, T., & Lutsey, P. L. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12514 · Cited by 5
Metadata
- Authors
- Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Freitas, M. C. S., Holberg, G., Kakkar, A. K., Haskell, L., van Bellen, B., Pap, A. F., Berkowitz, S. D., Verhamme, P., Wells, P. S., & Prandoni, P.
- Affiliations
- University of Ottawa (CA)
- University of Geneva (CH)
- University of Padua (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-30
- Volume
- 376
- Issue
- 13
- Pages
- 1211-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2595086780
- Cited by
- 787
- References
- 32
- Citations by year
- 2026: 58 · 2025: 77 · 2024: 65 · 2023: 49 · 2022: 78 · 2021: 97 · 2020: 92 · 2019: 96 · 2018: 123 · 2017: 50
- FWCI
- 104.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Ionis Pharmaceuticals
- Janssen Scientific Affairs
- Novo Nordisk
- Novo Nordisk Fonden (NNF12OC1015957)
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- venous thromboembolism, rivaroxaban, aspirin, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, low-dose rivaroxaban, thromboprophylaxis, direct oral anticoagulants, adverse events, dose comparison, post-thrombotic syndrome
- MeSH terms
- Rivaroxaban, Adult, Aged, Aspirin, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Kaplan-Meier Estimate, Venous Thromboembolism, Secondary Prevention, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.